Advertisement

Ischemic heart disease and plasmapheresis for cholesterol

  • I. Richichi

Abstract

Risk factors influence growth factors of the atheromatous plaque. LDL hypercholesterolemia is a very important growth factor, and it has to be eliminated in order to arrest plaque evolution. Theoretically plaque regression can be achieved only with the reduction of total blood cholesterol below 150 mg/dl. To obtain such level plasmapheresis should be added to pharmacological treatment which alone would be insufficient. There are various methods of cholesterol plasmapheresis but the most commonly used ones remain: cascade filtration and plasmapheresis with dextran sulphate.

Keywords

Atheromatous Plaque Dextran Sulphate Plaque Regression Important Growth Factor Total Blood Cholesterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Glueck, CJ. (1986) ’Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Am J Cardiol, 57: 35G–41G.PubMedCrossRefGoogle Scholar
  2. 2).
    Friedman, M., Bayers, SO. (1963) ’Observations concerning the evolution of atherosclerosis in the rabbit after cessation of cholesterol feeding. Am J Pathol, 43: 349–59PubMedGoogle Scholar
  3. 3).
    Blankenhorn, DH. (1982), ‘Lipoproteins and the progression and regression of atherosclerosis’. Cardiovasc Rev Rep, 3: 1063–71.Google Scholar
  4. 4).
    Thompson, GR. (1980) ‘Assessment of long-term plasma exchange for familial hypercolesterolemia’. Br Heart J. 43: 680–8.PubMedCrossRefGoogle Scholar
  5. 5).
    Malinow, MR. (1983) ’Regression of atherosclerosis in humans. A new frontier. Postgrad Med; 73: 232–5. 239–42.Google Scholar
  6. 6).
    Chait, A. (1987) ’Progression of atherosclerosis: the cellular biology. Eur Heart J. 8 (suppl H): 15–22.PubMedGoogle Scholar
  7. 7).
    Anitschkow, NN., Chacariw, S. (1913) Uber experimentelle Cholesterin stentose und ihr Bedeutung fur die Entstehung einiger pathologische Prozesse. Z. Allg Pathol Anat; 24: 1–9.Google Scholar
  8. 8).
    Armstrong, ML., Megan, MB (1972) ’Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res; 30: 675–80.PubMedGoogle Scholar
  9. 9).
    Clarkson, TB., Lehner, NDM., Wagner, WD. et al. (1980) ’A study of athe rosclerosis regression in Macaca mulatta. 1 design of experiment and lesion induction. Am Pathol; 100: 633.Google Scholar
  10. 10).
    Malinow, MR. (1981) ’Regression of atherosclerosis in humans. Fact or myth? Circulation 64: 1–3.PubMedCrossRefGoogle Scholar
  11. 11).
    Blankenhorn, DH, Nessim, SA., Johnson, RL et al. (1987) ’Beneficial effects of colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Jama 257: 3233–40.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • I. Richichi
    • 1
  1. 1.Cardiovascular Prevention CenterPoliclinico S. MatteoPaviaItaly

Personalised recommendations